Patient Perspectives in Squamous Cell Carcinoma Clinical Trials
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT05929547
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Clinical research participation has historically been heavily biased toward specific demographics. This study will invite several participants to gather a wide range of information on clinical trial experiences for squamous cell carcinoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of squamous cell carcinoma. People with squamous cell carcinoma who are invited to take part in clinical research will benefit from the analysis of the data.
Key Dates
- Start date
- Jul 31, 2024
- Status verified
- Jun 2023
- Primary completion
- Jul 31, 2025
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Number of patients who decide to enroll in a squamous cell carcinoma clinical trial [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill(415) 900-4227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 | - |
Find similar trials in San Francisco, CA
Related Studies
- Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckPHASE2 · Recruiting · Alain Algazi · San Francisco, California
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisPHASE1/PHASE2 · Recruiting · Neonc Technologies, Inc. · Beverly Hills, California
- A Study of VET3-TGI in Patients With Solid TumorsPHASE1 · Recruiting · KaliVir Immunotherapeutics · Los Angeles, California
- Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB SkinPHASE2 · Recruiting · Stanford University · Redwood City, California